ArticleMolecular biology reports2026
Rational engineering and yeast surface display of Epinecidin-1 peptides reveal antimicrobial activity and selective anticancer effects.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe global escalation of antimicrobial resistance has created an urgent demand for novel antimicrobial strategies beyond conventional antibiotics. Antimicrobial peptides (AMPs) constitute a key component of innate immunity and display broad-spectrum activity; however, their clinical translation is often limited by host toxicity, instability, and insufficient selectivity. METHODS AND
resultsIn this study, amino acid sequence of Epinecidin-1 (Epi-1), a marine-derived AMP isolated from Epinephelus coioides, was engineered using a rational design strategy and displayed on the surface of Saccharomyces cerevisiae via yeast surface display. Nine Epi-1 peptide variants differing in net charge and molecular weight were generated. Their surface expression was verified by flow cytometry, and selected variants were inactivated and evaluated for antimicrobial activity against six clinically relevant bacterial pathogens. Cytotoxicity and antiproliferative effects were also assessed using human embryonic kidney cells (HEK293) and MDA-MB-231 triple-negative breast cancer cells. Several Epi-1 variants exhibited efficient surface display and significant antimicrobial activity. No cytotoxic effects were observed in HEK293 cells across tested concentrations. However, they induced a time-dependent reduction in MDA-MB-231 cell viability.
conclusionThese findings demonstrate that yeast-displayed Epinecidin-1 variants retain antimicrobial efficacy while exhibiting minimal toxicity toward normal cells. The study highlights yeast surface display as a powerful platform for engineering and screening AMP derivatives for therapeutic and cosmetic applications.
Indexed as
Identifiers
41949677What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.